Association between VEGF Gene Polymorphism -634G>C and Risk of Colorectal Cancer

Asri Tambunan; Gontar Alamsyah Siregar; Masrul Lubis

doi:10.3889/oamjms.2022.8714

Authors

Asri Tambunan Department of Internal Medicine, Faculty of Medicine, Universitas Muhammadiyah Sumatera Utara, Medan, Indonesia
Gontar Alamsyah Siregar Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Masrul Lubis Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.8714

Keywords:

Cancer, Colorectal, Genetic, Polymorphism, Risk

Abstract

BACKGROUND: Genetic and environmental factors play an important role in the pathogenesis of colorectal cancer. Angiogenesis is a central process in carcinogenesis and is affected by vascular endothelial growth factor (VEGF). Several genetic variations, such as polymorphism, may alter VEGF expression and influence the risk of colorectal cancer.

AIM: The objective of this study was to determine the association between VEGF gene polymorphism -634G>C and risk of colorectal cancer.

METHODS: A cross-sectional study was conducted at Haji Adam Malik general hospital and its sister hospitals. Subjects were obtained by consecutive sampling. Inclusion criteria for case and control groups were patients with colorectal cancer and healthy subject, respectively, aged 18 years or older and willing to participate in the study. Exclusion criteria were patients with systemic comorbidities or malignancies in other organs. Each subject undergoes an interview, colonoscopy, biopsy, serum VEGF level measurement, and VEGF polymorphism -634G>C evaluation.

RESULTS: Eighty subjects were enrolled and distributed into case and control groups. Males were dominant in both groups, with a mean age of older than 55 years. Most lesions were in the rectum and 45% of subjects had moderately differentiated cancer. The median serum VEGF level in the case group was higher than the control group (2,175.1 pg/mL vs. 253 pg/mL; p < 0.001). VEGF gene polymorphism -634G > C was associated with the risk of colorectal cancer (p = 0.048). GG and GC genotypes had 1.89 times higher risk of colorectal cancer compared to the CC genotype. GG genotype and G allele had the highest serum VEGF levels.

CONCLUSION: There is an association between VEGF gene polymorphism -634G>C and risk of colorectal cancer in this study.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Smith RET, Renaud RC, Hoffman E. Colorectal cancer market. Nat Rev Drug Discov. 2004;3(6):471-2. https://doi.org/10.1038/nrd1419 PMid:15214331 DOI: https://doi.org/10.1038/nrd1419

Dobre M, Dinu DE, Panaitescu E, Bîrlă RD, Iosif CL, Boeriu M, et al. KRAS gene mutations prognostic factor in colorectal cancer? Rom J Morphol Embryol. 2015;56(2 Suppl):671-8. PMid:26429158

Calva AM, Acevedo TM. Review and general update on colorectal cancer. Anal Radiol Méx. 2009;8:99-115.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. https://doi.org/10.3322/caac.21254 PMid:25559415 DOI: https://doi.org/10.3322/caac.21254

Granados-Romero JJ, Valderrama-Trevino A, Flores EH, Barrera-Mera B, Herrera M, Uriarte-Ruiz K, et al. Colorectal cancer: A review. Int J Res Med Sci. 2017;5:4667-76. http://doi.org/10.18203/2320-6012.ijrms20174914 DOI: https://doi.org/10.18203/2320-6012.ijrms20174914

Padang MS, Rotty L. Adenokarsinoma kolon: laporan kasus. e-Clinic. 2020;8:229-36. https://doi.org/10.35790/ecl.v8i2.30539 DOI: https://doi.org/10.35790/ecl.v8i2.30539

Hav M, Eav S, Ky V, Cuvelier C, In S, Kong R, et al. Colorectal cancer in young Cambodians. Asian Pac J Cancer Prev. 2011;12(4):1001-5. PMid:21790241

Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. Molecular profile of colorectal cancer in Indonesia: is there another pathway. Gastroenterol Hepatol Bed Bench. 2012;5(2):71-8. PMid:24834203

Campos FG. Colorectal cancer in young adults: A difficult challenge. World J Gastroenterol. 2017;23(28):5041-4. https://doi.org/10.3748/wjg.v23.i28.5041 PMid:28811701 DOI: https://doi.org/10.3748/wjg.v23.i28.5041

Kuipers E, Grady W, Lieberman D. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. https://doi.org/10.1038/nrdp.2015.65 PMid:27189416 DOI: https://doi.org/10.1038/nrdp.2015.65

Recio-Boiles A, Cagir B. Colon Cancer. Treasure Island, FL: StatPearls Publishing; 2022.

Chang WH, Cerione RA, Antonyak MA. Extracellular vesicles and their roles in cancer progression. Methods Mol Biol. 2021;2174:143-70. https://doi.org/10.1007/978-1-0716-0759-6_10 PMid:32813249 DOI: https://doi.org/10.1007/978-1-0716-0759-6_10

Martins SF, Reis RM, Rodrigues AM. Baltazar F, Filho AL. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol. 2011;10(6):272-80. https://doi.org/10.5306/wjco.v2.i6.272 PMid:21773077 DOI: https://doi.org/10.5306/wjco.v2.i6.272

Pang RW, Poon RT. Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag. 2006;2(2):97-108. https://doi.org/10.2147/vhrm.2006.2.2.97 PMid:17319453 DOI: https://doi.org/10.2147/vhrm.2006.2.2.97

Svagzdys S, Lesauskaite V, Pavalkis D, Nedzelskiene I, Pranys D, Tamelis A. Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer. 2009;9:95. https://doi.org/10.1186/1471-2407-9-95 PMid:19323831 DOI: https://doi.org/10.1186/1471-2407-9-95

Spacek J, Vocka M, Netikova I, Skalova H, Dundr P, Konopasek B, et al. Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls. Immunol Invest. 2018;47(7):643-53. https://doi.org/10.1080/08820139.2018.1480030 PMid:29924680 DOI: https://doi.org/10.1080/08820139.2018.1480030

Sa-Nguanraksa D, O-Charoenrat P. The role of vascular endothelial growth factor A polymorphisms in breast cancer. Int J Mol Sci. 2012;13(11):14845-64. https://doi.org/10.3390%2Fijms131114845 PMid:23203097 DOI: https://doi.org/10.3390/ijms131114845

Eng L, Liu G. VEGF pathway polymorphisms as prognostic and pharmacogenetics factors in cancer: A 2013 update. Pharmacogenomics. 2013;14(13):1659-67. https://doi.org/10.2217/pgs.13.165 PMid:24088136 DOI: https://doi.org/10.2217/pgs.13.165

Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF- 634G>C promoter/polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009;9:77. https://doi.org/10.1186/1471-230x-9-77 DOI: https://doi.org/10.1186/1471-230X-9-77

Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi A, Al-Bahrani B. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms a case-control study in an Omani population. Mol Carcinog. 2009;48(12):1170-6. https://doi.org/10.1002/mc.20572 PMid:19676106 DOI: https://doi.org/10.1002/mc.20572

Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual dismorphism in colon cancer. Front Oncol. 2020;10:607909. https://doi.org/10.3389/fonc.2020.607909 PMid:33363037 DOI: https://doi.org/10.3389/fonc.2020.607909

White A, Ironmonger L, Steele RJ, Ormiston-Smith N, Crawford C, Seims A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer. 2018;18(1):906. https://doi.org/10.1186/s12885-018-4786-7 PMid:30236083 DOI: https://doi.org/10.1186/s12885-018-4786-7

Gao R, Neutel I, Wai E. Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada. J Public Health (Oxf). 2008;30(2):194-201. https://doi.org/10.1093/pubmed/fdn019 PMid:18445612 DOI: https://doi.org/10.1093/pubmed/fdn019

Steele SR, Park GE, Johnson EK, Martin MJ, Stojadinovic A, Maykel JA, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum. 2014;57(3):303-10. https://doi.org/10.1097/dcr.0b013e3182a586e7 PMid:24509451 DOI: https://doi.org/10.1097/DCR.0b013e3182a586e7

Moore KJ, Sussman DA, Koru-Sengul T. Age-specific risk factors for advanced stage colorectal cancer. 1981-2013. Prev Chronic Dis. 2018;15:170274. https://doi.org/10.5888/pcd15.170274 DOI: https://doi.org/10.5888/pcd15.170274

Ellis L, Abrahao R, McKinley M, Yang J, Somsouk M, Marchand LL, et al. Colorectal cancer incidence trends by age, stage, and racial/ethnic group in California, 1990-2014. Cancer Epidemiol Biomarkers Prev. 2018;27(9):1011-8. https://doi.org/10.1158/1055-9965.epi-18-0030 PMid:30115679 DOI: https://doi.org/10.1158/1055-9965.EPI-18-0030

Katz M, Parrish ME, Li E, Zhang Y, Zhu W, Shroyer K, et al. The effect of race/ethnicity on age of colon cancer diagnosis. J Health Dispar Res Pract. 2013;6(1):62-9. https://www.ncbi.nlm.nih.gov/pubmed/25995971 PMid:25995971

Ollberding NJ, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Racial/ethnic differences in colorectal cancer risk: The multiethnic cohort study. Int J Cancer. 2011;129:1899-906. https://doi.org/10.1002%2Fijc.25822 PMid:21128280 DOI: https://doi.org/10.1002/ijc.25822

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal cancer by tumor location rather than sideness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24(5):1062-72. https://doi.org/10.1158/1078-0432.ccr-17-2484 PMid:29180604 DOI: https://doi.org/10.1158/1078-0432.CCR-17-2484

Darmadi D, Ruslie RH, Pakpahan C. Vascular endothelial growth factor levels difference among hepatocellular cancer patients on barcelona clinic liver cancer staging. Open Access Maced J Med Sci. 2021;9:797-800. https://doi.org/10.3889/oamjms.2021.6598 DOI: https://doi.org/10.3889/oamjms.2021.6598

Ruslie RH, Darmadi D, Siregar GA. Vascular endothelial growth factor (VEGF) and neopterin levels in children with steroid-sensitive and steroid-resistant nephrotic syndrome. Med Arch (Sarajevo, Bosnia and Herzegovina). 2021;75(2):133-7. http://doi.org/10.5455/medarh.2021.75.133-137 PMid:34219873 DOI: https://doi.org/10.5455/medarh.2021.75.133-137

Zhu D, Yang Z, Miao X, Yang W, Jiang M, Chen Y. Association of serum vascular endothelial growth factor (VEGF) with colorectal cancer: A systematic review and meta-analysis. J Cancer Sci Clin Ther. 2020;4(1):15-31. https://doi.org/10.26502/jcsct.5079046 DOI: https://doi.org/10.26502/jcsct.5079046

Celen O, Kahraman I, Yildirim E, Berberoglu U. Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients. Neoplasma. 2004;51(4):293-9. PMid:15254661

Werther K, Christensen IJ, Nielsen HJ, Danish RANX05 Colorectal Cancer Study Group. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer. 2002;86(3):417-23. https://doi.org/10.1038%2Fsj.bjc.6600075 PMid:11875709 DOI: https://doi.org/10.1038/sj.bjc.6600075

Ljujic B, Radosavljevic G, Jovanovic I, Pavlovic S, Zdravkovic N, Milovanovic M, et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010;41(3):182-9. https://doi.org/10.1016/j.arcmed.2010.02.009 PMid:20682175 DOI: https://doi.org/10.1016/j.arcmed.2010.02.009

Lissoni P, Rovelli F, Malugani F, Brivio F, Fumagalli L, Gardani GS. Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers. 2003;18(2):152-2. https://doi.org/10.5301/jbm.2008.1731 PMid:12841685 DOI: https://doi.org/10.5301/JBM.2008.1731

Chen MH, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. VEGF -460TC polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal cancer. Pharmacogenomics J. 2011;11:227-36. https://doi.org/10.1038/tpj.2010.48 DOI: https://doi.org/10.1038/tpj.2010.48

Jannuzzi AT, Ozhan G, Yanar HT, Alpertunga B. VEGF gene polymorphisms and susceptibility to colorectal cancer. Genet Test Mol Biomarkers. 2015;19(3):133-7. https://doi.org/10.1089/gtmb.2014.0259 PMid:25635747 DOI: https://doi.org/10.1089/gtmb.2014.0259

Wang L, Ji S, Cheng Z. Vascular endothelial growth factor -2578C/A polymorphism and colorectal cancer risk: A meta-analysis. J Res Med Sci. 2015;20:811-7. DOI: https://doi.org/10.4103/1735-1995.168406

Park HM, Hong SH, Kim JW, Oh D, Hwang SG, An HJ, et al. Gender-specific association of the VEGF -2578C>A polymorphism in Korean patients with colon cancer. Anticancer Res. 2007;27(2B):2535-9. PMid:17695550

Bakhshian-Dehkordi E, Safei M, Fattahi S, Faghani M, Deris F, Chaleshtori MH. The association of VEGF rs833061 and rs2010963 polymorphisms with susceptibility to colorectal cancer in an Iranian population. Cancer Epidemiol. 2021;75:102041. https://doi.org/10.1016/j.canep.2021.102041 PMid:34592532 DOI: https://doi.org/10.1016/j.canep.2021.102041

Savabkar S, Chaleshi V, Farahbakhsh FB, Haghighi MM, Zali N, Mojarad EN, et al. VEGF gene +936C/T polymorphism decreases the risk of colorectal cancer. Eur J Oncol Environ Health. 2015;20:88-93.

Yang M, Xiao X, Xing X, Li X, Xia T, Long H. KRAS and VEGF gene 3’-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer. PLoS One. 2017;12:e0174140. https://doi.org/10.1371/journal.pone.0174140 PMid:28328959 DOI: https://doi.org/10.1371/journal.pone.0174140